<DOC>
	<DOC>NCT01813799</DOC>
	<brief_summary>This is a Phase II dose-ranging study to evaluate the effectiveness and safety of DA-9801 in the treatment of pain associated with diabetic neuropathy. Subjects will receive either 300mg, 600mg, 900mg or placebo, three times daily for eight weeks. During treatment, pain score by Likert numerical rating scale, Patient Global Impression of Improvement (PGI-I) and Change in Clinical Global Impression(CGI)are accessed to evaluate the effectiveness.</brief_summary>
	<brief_title>Study of DA-9801 to Treat Diabetic Neuropathic Pain</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>the age of 20 ~ 70 Type I or Type II Diabetes HbA1c â‰¤11% Patients with diabetic neuropathic pain for at least 3 months Patients corresponding to average pain level of 4 points or more for 24 hours evaluated with 11point Likert scale neuropathic pain due to other causes or another stronger pain other than neuropathic pain abnormal in blood pressure, weight, ALT/AST, Serum creatinine positive reaction in HIV, HBV, or HCV experience of suicide try or Mental Illness Medical History BDI(Beck Depression Inventory) grade exceeding 21 points chronic alcohol abuse history</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Diabetic Neuropathies</keyword>
</DOC>